Department of Pharmacology, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Chennai, India
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation and systemic consequences. Due to the limitations of conventional therapeutic approaches, natural alternatives with anti-inflammatory and immunomodulatory properties are being explored. Raphanus sativus L. (R. sativus), a medicinal plant rich in bioactive compounds such as terpenes, glucosinolates, and flavonoids, holds potential as a treatment for RA. This study employs molecular docking and network pharmacology to investigate the therapeutic potential of R. sativus in RA. RA-related genes and R. sativus phytochemicals were analysed to identify overlapping targets. Molecular docking studies were conducted to assess interactions between key phytochemicals and inflammatory receptors. ADMET analysis was performed to evaluate pharmacokinetic properties. A total of 166 overlapping targets were identified between RA-related genes and R. sativus phytochemicals, suggesting a multi-targeted therapeutic approach. Molecular docking revealed strong interactions between key compounds quercetin, lutein, and violaxanthin and TREM-1, a crucial receptor in inflammatory pathways. ADMET analysis confirmed favorable pharmacokinetic properties, though variations in toxicity and absorption require further investigation. While in silico results highlight R. sativus as a promising plant-based therapy for RA, further in vivo and clinical studies are necessary to confirm its safety and efficacy.
Key words: Raphanus sativus L., rheumatoid arthritis, molecular docking, network pharmacology.
How to cite this article: Vijayan MR, Balakrishnan P, Ramanathan P, Yamini M, Patel S, Deciphering The Pharmacological Effects Of Raphanus Sativus L. In Rheumatoid Arthritis Through Network Pharmacology And Molecular Docking. Int J Drug Deliv Technol. 2026;16(2): 51-65. DOI: 10.25258/ijddt.16.2.7
Source of support: Nil.
Conflict of interest: None